Journal
BLOOD COAGULATION & FIBRINOLYSIS
Volume 32, Issue 3, Pages 225-228Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MBC.0000000000000999
Keywords
coronavirus disease 2019 coagulopathy; ROtational ElastoMEtry; sepsis; thrombelastography; viscoelastic hemostatic assay
Categories
Funding
- NIGMS NIH HHS [R01 GM123010] Funding Source: Medline
Ask authors/readers for more resources
COVID-19-associated coagulopathy is characterized by significant hypercoagulability and fibrinolysis shutdown, and viscoelastic hemostatic assays (VHA) may provide a useful tool in identifying this abnormal coagulation state. However, its application in sepsis patients and specifically in the context of COVID-19 is still not well-defined, with limited large randomized trials available.
Coronavirus disease 2019 (COVID-19)-associated coagulopathy is unusual, poorly defined and is linked with significant hypercoagulability and microthrombotic and macrothrombotic complications leading to worse outcomes and higher mortality. Conventional coagulation assays do not always actively reflect these derangements and might fail to detect this coagulopathy. Viscoelastic hemostatic assays (VHA) provide a possible tool that adds to conventional coagulation assays in identifying this hypercoagulable state. VHA has been mostly used in surgery and trauma but it's still not well defined in sepsis patients with lack of large randomized trials. Few studies described VHA findings in patients with COVID-19 showing significant hypercoagulability and fibrinolysis shutdown. Clinicians taking care of these patients might have little experience interpreting VHA results. By reviewing the available literature on the use of VHA in sepsis, and the current knowledge on COVID-19-associated coagulopathy we provide clinicians with a practical guide on VHA utilization in patients with COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available